Evidence map›Paper›PMID 41617258›Full record

ArticleBMJ open ophthalmology2026

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.

Amr Saad, Christina Plasencia, Justus Garweg, Isabel Barbara Pfister, Marion R Munk, Chiara Maria Eandi, Sandrine Anne Zweifel, Gabriela Grimaldi, Nicolò Bartolomeo, Richard Stillenmunkes and 11 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Real-world outcomes of faricimab in treatment-naïve diabetic macular edema: The Middle East perspective.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Amr SaadDepartment of Ophthalmology, Stadtspital Zurich Triemli, Zürich, Switzerland.
Christina PlasenciaMedical Retina & Clinical Research Department, Vista Klinik, Binningen, Switzerland.
Justus GarwegBerner Augenklinik am Lindenhofspital, Bern, Switzerland.
Isabel Barbara PfisterSwiss Eye Institute, Bern, Switzerland.ORCID http://orcid.org/0000-0001-8752-8390
Marion R MunkOphthalmology, Inselspital, University Hospital Bern, Bern, Switzerland.
Chiara Maria EandiDepartment of Ophthalmology, Jules Gonin Eye Hospital, Lausanne, Switzerland.
Sandrine Anne ZweifelUniversitatsspital Zurich Augenklinik und Poliklinik, Zurich, Switzerland.
Gabriela GrimaldiOphthalmology, Institute of Clinical Neurosciences of Southern Switzerland, Lugano, Switzerland.
Nicolò BartolomeoResearch Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Richard StillenmunkesDepartment of Ophthalmology, Inselspital University Hospital Bern, Bern, Switzerland.
Christin SchildSwiss Eye Institute, Bern, Switzerland.
Jennifer CattaneoDepartment of Ophthalmology, Jules Gonin Eye Hospital, Lausanne, Switzerland.
Felix GabathulerUniversitatsspital Zurich Augenklinik und Poliklinik, Zurich, Switzerland.
Moreno MenghiniOphthalmology, Institute of Clinical Neurosciences of Southern Switzerland, Lugano, Switzerland.
Aude AmbersinResearch Center, Swiss Visio Montchoisi, Lausanne, Switzerland.
Jacqueline FroehlichDepartment of Ophthalmology, University of Basel, Basel, Switzerland.
Dmitri ArtemievDepartment of Ophthalmology, Kantonsspital St Gallen, St. Gallen, Switzerland.
Andreas WeinbergerPallas Kliniken AG, Olten, Switzerland.
Hamza MohamedDepartment of Ophthalmology, Stadtspital Zurich Triemli, Zürich, Switzerland.
Gabor Mark SomfaiDepartment of Ophthalmology, Stadtspital Zurich Triemli, Zürich, Switzerland.
Katja HatzMedical Retina & Clinical Research Department, Vista Klinik, Binningen, Switzerland katja.hatz@unibas.ch.ORCID http://orcid.org/0000-0003-2807-0310

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsEvaluate the efficacy and safety of faricimab for treatment-naïve and pre-treated diabetic macular oedema (DME) in a real-world setting.

methodsThis multicentre, retrospective cohort study examined consecutive DME patients treated with faricimab for ≥1 year. Data were collected at predefined time points. Primary outcomes were mean changes in corrected visual acuity (VA), centre-point retinal thickness (CRT) and central subfield thickness (CST) and treatment intervals and adverse events (AEs).

results184 eyes with DME were included: 61 (33.2%) were treatment-naïve, and 123 (66.8%) were pretreated. In treatment-naïve eyes, VA improved from 69.7±15 Early Treatment of Diabetic Retinopathy Study letters at baseline to 73.9±14.1 after 12 months (p=0.014), while it remained stable in pretreated eyes (71.2±14.2 vs 73.0±12.9; p=0.14). CST decreased significantly in both groups (treatment-naïve (366.1±108.3 µm to 316.4±113.5 µm, p<0.001); pretreated (339.1±93.1 µm to 298.3±65.8 µm, p<0.001)). Thirty-one percent of naïve eyes and 21.1% of pretreated eyes were completely dry after 12 months. In treatment-naïve eyes, the mean treatment interval was 12.7±6.4 weeks at 12 months. In pretreated eyes, the interval increased from 6.0±3.0 to 7.8±3.6 weeks (p<0.001). Over 12 months, 8.1±2.1 and 9.4±2.5 injections were administered to naïve and pretreated eyes, respectively (p<0.001). Of the five recorded AEs, two cases of non-infectious intraocular inflammation and one cerebrovascular event were reported.

conclusionOver 12 months, faricimab demonstrated good efficacy and safety in both treatment-naïve and pretreated eyes with DME. There was a reduction in CST and improved VA in treatment-naïve eyes and stable VA in pretreated eyes. The low number of AEs supports a favourable risk-benefit profile of faricimab in a real-world setting.

Indexed as

Antibodies, BispecificDiabetic RetinopathyMacular EdemaRetinaVisual AcuityAgedAngiogenesis InhibitorsFemaleFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedRetrospective StudiesSwitzerlandTime FactorsAngiogenesis InhibitorsAntibodies, BispecificfaricimabMaculaRetinaTreatment MedicalVitreous

Identifiers

PMID41617258
PMCPMC12863342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.